Q4 2024 Management View CEO Jeffrey Graves emphasized the impact of a change in accounting estimate for the regenerative medicine program, which resulted in a $9 million reduction in Q4 revenue. He ...
On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our ...
Operator Greetings and welcome to the 3D Systems fourth quarter and fiscal year 2024 earnings conference call and webcast. At ...
Copyright © 2025 MarketWatch, Inc. All rights reserved.
Want 15% off at Adore Beauty? Sign up to the latest news at Marie Claire. Delivering a big impact on both the look of your space and your sleep quality, there are few things as important as your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback